GROUP SUBSIDIARIES*
|
At December 31, 2018 |
|
Country |
|
Percentage of voting |
|
Wholly owned subsidiaries |
|
|
|
|
|
AstraZeneca AB |
|
Sweden |
|
100 |
|
AstraZeneca Biotech AB |
|
Sweden |
|
100 |
|
AstraZeneca Intermediate Holdings Limited |
|
England |
|
100 |
|
AstraZeneca Pharmaceuticals LP |
|
United States |
|
100 |
|
AstraZeneca Treasury Limited |
|
England |
|
100 |
|
AstraZeneca UK Limited |
|
England |
|
100 |
|
IPR Pharmaceuticals, Inc. |
|
Puerto Rico |
|
100 |
|
KuDOS Pharmaceuticals Limited |
|
England |
|
100 |
|
MedImmune, LLC |
|
United States |
|
100 |
|
ZS Pharma Inc. |
|
United States |
|
100 |
|
Subsidiaries where the effective ownership is less than 100% |
|
|
|
|
|
Acerta Pharma B.V. |
|
Netherlands |
|
55 |
* Subsidiary companies which would be deemed to be a “significant subsidiary” in accordance with rule 1-02(w) of Regulation S-X as at December 31, 2018.